ArticleThe oncologist2013

Erlotinib and gefitinib, epidermal growth factor receptor kinase inhibitors, may treat non-cancer-related tumor necrosis factor-α mediated inflammatory diseases.

Marvin B BrooksPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.